Cognition Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.43
- Today's High:
- $1.4976
- Open Price:
- $1.43
- 52W Low:
- $1.07
- 52W High:
- $3.83
- Prev. Close:
- $1.44
- Volume:
- 8798
Company Statistics
- Market Cap.:
- $86.66 million
- Book Value:
- 1.222
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -51.64%
- Return on Equity TTM:
- -56.15%
Company Profile
Cognition Therapeutics Inc had its IPO on 2021-10-08 under the ticker symbol CGTX.
The company operates in the Healthcare sector and Biotechnology industry. Cognition Therapeutics Inc has a staff strength of 22 employees.
Stock update
Shares of Cognition Therapeutics Inc opened at $1.43 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.43 - $1.5, and closed at $1.44.
This is a 0% increase from the previous day's closing price.
A total volume of 8,798 shares were traded at the close of the day’s session.
In the last one week, shares of Cognition Therapeutics Inc have slipped by -7.69%.
Cognition Therapeutics Inc's Key Ratios
Cognition Therapeutics Inc has a market cap of $86.66 million, indicating a price to book ratio of 1.9673 and a price to sales ratio of 0.
In the last 12-months Cognition Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-43025000. The EBITDA ratio measures Cognition Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cognition Therapeutics Inc’s operating margin was 0% while its return on assets stood at -51.64% with a return of equity of -56.15%.
In Q1, Cognition Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cognition Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.29 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cognition Therapeutics Inc’s profitability.
Cognition Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3479. Its price to sales ratio in the trailing 12-months stood at 0.
Cognition Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $45.66 million
- Total Liabilities
- $7.47 million
- Operating Cash Flow
- $-41000.00
- Capital Expenditure
- $41000
- Dividend Payout Ratio
- 0%
Cognition Therapeutics Inc ended 2024 with $45.66 million in total assets and $0 in total liabilities. Its intangible assets were valued at $45.66 million while shareholder equity stood at $35.78 million.
Cognition Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $7.47 million in other current liabilities, 29000.00 in common stock, $-121573000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.81 million and cash and short-term investments were $38.81 million. The company’s total short-term debt was $584,000 while long-term debt stood at $0.
Cognition Therapeutics Inc’s total current assets stands at $42.80 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.61 million compared to accounts payable of $3.12 million and inventory worth $0.
In 2024, Cognition Therapeutics Inc's operating cash flow was $-41000.00 while its capital expenditure stood at $41000.
Comparatively, Cognition Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.44
- 52-Week High
- $3.83
- 52-Week Low
- $1.07
- Analyst Target Price
- $7.75
Cognition Therapeutics Inc stock is currently trading at $1.44 per share. It touched a 52-week high of $3.83 and a 52-week low of $3.83. Analysts tracking the stock have a 12-month average target price of $7.75.
Its 50-day moving average was $1.63 and 200-day moving average was $1.98 The short ratio stood at 2.19 indicating a short percent outstanding of 0%.
Around 779.7% of the company’s stock are held by insiders while 4347.6% are held by institutions.
Frequently Asked Questions About Cognition Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer’s disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.